Protective effect of A(H5N8) stockpiled vaccine against a virus genetically identical to a human isolate of bovine A(H5N1) influenza virus
This finding highlights the vaccine's potential utility during the early phase of an emerging pandemic threat.
Maternal RSVpreF Vaccine Effectiveness Against Respiratory Syncytial Virus in Hospitalized Infants
maternal RSVpreF vaccination was associated with 78% to 81% reduction in RSV-associated hospitalization from birth through 6 months of age, with the highest vaccine effectiveness in earliest age intervals.
The receptor landscape of influenza A viruses
Authors discuss the structural determinants of sialic acid and MHC-II receptor engagement, the plasticity of HA receptor-binding sites, and the consequences of exclusive or dual receptor usage on host range and zoonotic potential.
First Ecuadorian Pediatric Case of Multisystem and Neurological Involvement Associated with Influenza A—H5N1 Virus—Case Report
This report describes the first confirmed Ecuadorian pediatric case of H5N1-associated encephalitis and multisystem organ failure in a previously healthy 9-year-old female following direct contact with infected poultry.
Genomic Surveillance Uncovers the Silent Spread of Avian Influenza Virus (H5N1 2.3.4.4b) Among Wild Birds and Mammals Along Brazil’s Southern Coast
Reinforces the importance of continuous genomic surveillance, especially in AIV hosts that do not show signs of infection, to enhance the One-Health assessment approach.
Oseltamivir Resistance in Human Influenza A(H5N1) and A(H7N9) Infections: A Mini Review
The objective of this article is to review human cases of A(H5N1) and A(H7N9) infections for which mutations of oseltamivir resistance were detected.
A bovine H5N1 virus efficiently replicates in differentiated human nasal epithelial cells
H5N1 virus (H5N1Tex/24) isolated from bovine milk in Texas in 2024 replicates just as efficiently in differentiated human nasal epithelial cells as a pandemic H1N1 virus strain from 2009.
Effectiveness of baloxavir marboxil in nonhuman primates infected with highly pathogenic avian influenza A(H7N9) virus
Findings highlight the importance of early antiviral intervention and support BXM use as a potential countermeasure against HPAI A(H7N9) virus infection.